Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04748601 · ClinicalTrials.gov registry record · Phase 4
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
A Phase 4 study of Migraine Disorders, sponsored by Upsher-Smith Laboratories.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 132
- Enrollment target
- 15
- Study locations
NCT04748601: Recruiting Phase 4 study of Migraine Disorders, sponsored by Upsher-Smith Laboratories.
NCT04748601 is a Phase 4 study of Migraine Disorders that is actively recruiting participants, run by Upsher-Smith Laboratories. The registered enrollment target is 132 participants, below the 309-participant average among 21 other Migraine Disorders trials with a reported enrollment target (57% lower). The trial reports 15 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04748601, a Phase 4 study of Migraine Disorders, is actively recruiting participants, sponsored by Upsher-Smith Laboratories.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 132 participants
- Enrollment target
- 15
- Study locations
Study Summary
A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Qudexy XR
Study Locations (15)
Florida
- Upsher-Smith Clinical Trial Site #12 - Loxahatchee Groves
- Upsher-Smith Clinical Trial Site #8 - Orlando
- Upsher-Smith Clinical Trial Site #14 - Tampa
Oregon
- Upsher-Smith Clinical Trial Site #6 - Portland
- Upsher-Smith Clinical Trials Site #7 - Springfield
Alabama
- Upsher-Smith Clinical Trial Site #5 - Birmingham
California
- Upsher-Smith Clinical Trial Site #15 - La Jolla
Colorado
- Upsher-Smith Clinical Trials Site #3 - Aurora
Connecticut
- Upsher-Smith Clinical Trial Site #1 - Stamford
Michigan
- Upsher-Smith Clinical Trial Site #2 - Ann Arbor
Mississippi
- Upsher-Smith Clinical Trial Site #11 - Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2021-02-19 |
| Est. Completion | 2026-09 |
| Phase | Phase 4 |
What NCT04748601 shows while recruiting
NCT04748601 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 309-participant average among 21 other Migraine Disorders trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Migraine Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04748601 lists 15 locations in 12 states (Florida, Oregon, Alabama).
Frequently Asked Questions
What is clinical trial NCT04748601 about?
NCT04748601 is a clinical study titled "Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old". A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.
What is the current status of trial NCT04748601?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 132 participants. The study started on 2021-02-19. Estimated completion is 2026-09.
What conditions does trial NCT04748601 study?
This clinical trial studies the following conditions: Migraine Disorders.
What interventions are being tested in trial NCT04748601?
The interventions under investigation include: Placebo (DRUG), Qudexy XR (DRUG).
Who is sponsoring clinical trial NCT04748601?
This trial is sponsored by Upsher-Smith Laboratories, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04748601 being conducted?
This trial has 15 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04748601's enrollment target sits among peer trials
132 15th of 21 higher than 7 of 21 other Migraine Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period
COMPLETED · Phase 4
-
Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults
COMPLETED · Phase 4
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
-
Mind Body Balance for Pediatric Migraine
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI